NY-ESO-1 TCR/IL-15 NK Clinical Trials
2 recruitingDrug
Phase 12Phase 21
Showing 1–2 of 2 trials
Recruiting
Phase 1
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
Synovial SarcomaMyxoid/Round Cell Liposarcoma
M.D. Anderson Cancer Center44 enrolled1 locationNCT06083883
Recruiting
Phase 1Phase 2
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
Myeloma
M.D. Anderson Cancer Center44 enrolled1 locationNCT06066359